Summary

KEY FINDINGS
The global botulinum toxin market is predicted to record a 10.07% CAGR during the forecast period, 2023-2032. The surge in demand for aesthetic procedures, the rising geriatric population, and the demand for non-invasive cosmetic procedures driving the botulinum toxin market drive the market growth.
MARKET INSIGHTS
Botulinum toxin is a neurotoxin produced by certain Clostridium botulinum strains and is utilized for both therapeutic and cosmetic purposes. Its cosmetic form, commonly referred to as Botox by patients, is an injectable that temporarily reduces or eliminates wrinkles and fine lines on the face. The most frequently treated areas include frown lines, forehead wrinkles, and crow’s feet around the eyes, but it is also used to treat other areas such as gummy smiles, lip lines, overactive jaw muscles, and thick neck bands.
Several factors, including increasing demand for aesthetic procedures, growth in non-invasive cosmetic procedures, research and development initiatives, and a rise in the geriatric population, are propelling the global market for botulinum toxin. With an increasing number of people worldwide undergoing aesthetic procedures each year, the market for botulinum toxin is expected to experience significant growth in the coming years.
REGIONAL INSIGHTS
The global botulinum toxin market analysis comprises a study of Europe, Asia-Pacific, North America, and Rest of World. North America is expected to dominate the market due to the growing R&D efforts to broaden therapeutic uses and an increase in cosmetic issues like crow’s feet and medial canthal wrinkles. Additionally, factors such as disposable personal income and per capita disposable income in the United States are expected to fuel the growth of the botulinum toxin market in North America.
COMPETITIVE INSIGHTS
Market players invest in R&D, label extension, and acquisitions to enhance product offerings. Innovation, advertising, competitive strategies, and high concentration ratio increase industry rivalry.
Major market players include Medytox, Merz Pharma, Lanzhou Institute of Biological Products Co Ltd, etc.
Our report offerings include:
• Explore key findings of the overall market
• Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
• Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
• Market Segmentation caters to a thorough assessment of key segments with their market estimations
• Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
• Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
• Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
• Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS
1. RESEARCH SCOPE & METHODOLOGY
1.1. STUDY OBJECTIVES
1.2. METHODOLOGY
1.3. ASSUMPTIONS & LIMITATIONS
2. EXECUTIVE SUMMARY
2.1. MARKET SIZE & ESTIMATES
2.2. MARKET OVERVIEW
2.3. SCOPE OF STUDY
2.4. CRISIS SCENARIO ANALYSIS
2.4.1. IMPACT OF COVID-19 ON BOTULINUM TOXIN MARKET
2.5. MAJOR MARKET FINDINGS
2.5.1. FAVORABLE REGULATORY APPROVALS ADD TO MARKET GROWTH
2.5.2. GROWING AWARENESS ABOUT ‘NOTOX’
2.5.3. INFLATING COSMETIC TOURISM ADDS TO THE DEMAND FOR BOTULINUM TOXIN
3. MARKET DYNAMICS
3.1. KEY DRIVERS
3.1.1. SURGE IN DEMAND FOR AESTHETIC PROCEDURES
3.1.2. RISING GERIATRIC POPULATION
3.1.3. GROWING DEMAND FOR NON-INVASIVE COSMETIC PROCEDURES
3.2. KEY RESTRAINTS
3.2.1. CONCERNS REGARDING THE ADVERSE EFFECTS OF BOTULINUM TOXIN
3.2.2. LACK OF REIMBURSEMENT POLICIES SUPPORTING COSMETIC PROCEDURES
4. KEY ANALYTICS
4.1. KEY MARKET TRENDS
4.2. PORTER’S FIVE FORCES ANALYSIS
4.2.1. BUYERS POWER
4.2.2. SUPPLIERS POWER
4.2.3. SUBSTITUTION
4.2.4. NEW ENTRANTS
4.2.5. INDUSTRY RIVALRY
4.3. GROWTH PROSPECT MAPPING
4.3.1. GROWTH PROSPECT MAPPING FOR UNITED STATES
4.3.2. GROWTH PROSPECT MAPPING FOR GERMANY
4.3.3. GROWTH PROSPECT MAPPING FOR CHINA
4.3.4. GROWTH PROSPECT MAPPING FOR BRAZIL
4.4. MARKET MATURITY ANALYSIS
4.5. MARKET CONCENTRATION ANALYSIS
5. MARKET BY TYPE
5.1. TYPE A BOTULINUM TOXIN
5.2. TYPE B BOTULINUM TOXIN
6. MARKET BY USER DEMOGRAPHIC
6.1. WOMEN
6.2. MEN
7. MARKET BY APPLICATION
7.1. MEDICAL
7.1.1. CHRONIC MIGRAINE
7.1.2. MUSCLE SPASM
7.1.3. OVERACTIVE BLADDER
7.1.4. HYPERHIDROSIS
7.1.5. OTHER MEDICAL APPLICATIONS
7.2. AESTHETIC
7.2.1. CROW’S FEET
7.2.2. FOREHEAD LINES
7.2.3. FROWN LINES/GLABELLAR
7.2.4. SQUARE JAW/MASSETER
7.2.5. OTHER AESTHETIC APPLICATIONS
8. MARKET BY END-USER
8.1. SPECIALTY AND DERMATOLOGY CLINICS
8.2. HOSPITALS AND CLINICS
8.3. OTHER END-USERS
9. GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1. MARKET SIZE & ESTIMATES
9.1.2. NORTH AMERICA BOTULINUM TOXIN MARKET DRIVERS
9.1.3. NORTH AMERICA BOTULINUM TOXIN MARKET CHALLENGES
9.1.4. NORTH AMERICA BOTULINUM TOXIN MARKET REGULATORY FRAMEWORK
9.1.5. KEY PLAYERS IN NORTH AMERICA BOTULINUM TOXIN MARKET
9.1.6. COUNTRY ANALYSIS
9.1.6.1. UNITED STATES
9.1.6.1.1. UNITED STATES BOTULINUM TOXIN MARKET SIZE & OPPORTUNITIES
9.1.6.2. CANADA
9.1.6.2.1. CANADA BOTULINUM TOXIN MARKET SIZE & OPPORTUNITIES
9.2. EUROPE
9.2.1. MARKET SIZE & ESTIMATES
9.2.2. EUROPE BOTULINUM TOXIN MARKET DRIVERS
9.2.3. EUROPE BOTULINUM TOXIN MARKET CHALLENGES
9.2.4. EUROPE BOTULINUM TOXIN MARKET REGULATORY FRAMEWORK
9.2.5. KEY PLAYERS IN EUROPE BOTULINUM TOXIN MARKET
9.2.6. COUNTRY ANALYSIS
9.2.6.1. UNITED KINGDOM
9.2.6.1.1. UNITED KINGDOM BOTULINUM TOXIN MARKET SIZE & OPPORTUNITIES
9.2.6.2. GERMANY
9.2.6.2.1. GERMANY BOTULINUM TOXIN MARKET SIZE & OPPORTUNITIES
9.2.6.3. FRANCE
9.2.6.3.1. FRANCE BOTULINUM TOXIN MARKET SIZE & OPPORTUNITIES
9.2.6.4. ITALY
9.2.6.4.1. ITALY BOTULINUM TOXIN MARKET SIZE & OPPORTUNITIES
9.2.6.5. SPAIN
9.2.6.5.1. SPAIN BOTULINUM TOXIN MARKET SIZE & OPPORTUNITIES
9.2.6.6. NORDIC COUNTRIES
9.2.6.6.1. NORDIC COUNTRIES BOTULINUM TOXIN MARKET SIZE & OPPORTUNITIES
9.2.6.7. POLAND
9.2.6.7.1. POLAND BOTULINUM TOXIN MARKET SIZE & OPPORTUNITIES
9.2.6.8. REST OF EUROPE
9.2.6.8.1. REST OF EUROPE BOTULINUM TOXIN MARKET SIZE & OPPORTUNITIES
9.3. ASIA-PACIFIC
9.3.1. MARKET SIZE & ESTIMATES
9.3.2. ASIA-PACIFIC BOTULINUM TOXIN MARKET DRIVERS
9.3.3. ASIA-PACIFIC BOTULINUM TOXIN MARKET CHALLENGES
9.3.4. ASIA-PACIFIC BOTULINUM TOXIN MARKET REGULATORY FRAMEWORK
9.3.5. KEY PLAYERS IN ASIA-PACIFIC BOTULINUM TOXIN MARKET
9.3.6. COUNTRY ANALYSIS
9.3.6.1. CHINA
9.3.6.1.1. CHINA BOTULINUM TOXIN MARKET SIZE & OPPORTUNITIES
9.3.6.2. JAPAN
9.3.6.2.1. JAPAN BOTULINUM TOXIN MARKET SIZE & OPPORTUNITIES
9.3.6.3. INDIA
9.3.6.3.1. INDIA BOTULINUM TOXIN MARKET SIZE & OPPORTUNITIES
9.3.6.4. SOUTH KOREA
9.3.6.4.1. SOUTH KOREA BOTULINUM TOXIN MARKET SIZE & OPPORTUNITIES
9.3.6.5. SINGAPORE
9.3.6.5.1. SINGAPORE BOTULINUM TOXIN MARKET SIZE & OPPORTUNITIES
9.3.6.6. THAILAND
9.3.6.6.1. THAILAND BOTULINUM TOXIN MARKET SIZE & OPPORTUNITIES
9.3.6.7. AUSTRALIA & NEW ZEALAND
9.3.6.7.1. AUSTRALIA & NEW ZEALAND BOTULINUM TOXIN MARKET SIZE & OPPORTUNITIES
9.3.6.8. REST OF ASIA-PACIFIC
9.3.6.8.1. REST OF ASIA-PACIFIC BOTULINUM TOXIN MARKET SIZE & OPPORTUNITIES
9.4. REST OF WORLD
9.4.1. MARKET SIZE & ESTIMATES
9.4.2. REST OF WORLD BOTULINUM TOXIN MARKET DRIVERS
9.4.3. REST OF WORLD BOTULINUM TOXIN MARKET CHALLENGES
9.4.4. REST OF WORLD BOTULINUM TOXIN REGULATORY FRAMEWORK
9.4.5. KEY PLAYERS IN REST OF WORLD BOTULINUM TOXIN MARKET
9.4.6. REGIONAL ANALYSIS
9.4.6.1. LATIN AMERICA
9.4.6.1.1. LATIN AMERICA BOTULINUM TOXIN MARKET SIZE & OPPORTUNITIES
9.4.6.2. MIDDLE EAST & AFRICA
9.4.6.2.1. MIDDLE EAST & AFRICA BOTULINUM TOXIN MARKET SIZE & OPPORTUNITIES
10. COMPETITIVE LANDSCAPE
10.1. KEY STRATEGIC DEVELOPMENTS
10.1.1. ACQUISITIONS
10.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
10.1.3. PARTNERSHIPS
10.1.4. BUSINESS EXPANSIONS
10.2. COMPANY PROFILES
10.2.1. ABBVIE
10.2.1.1. COMPANY OVERVIEW
10.2.1.2. PRODUCT LIST
10.2.1.3. STRENGTHS & CHALLENGES
10.2.2. CANDELA MEDICAL
10.2.2.1. COMPANY OVERVIEW
10.2.2.2. PRODUCT LIST
10.2.2.3. STRENGTHS & CHALLENGES
10.2.3. DAEWOONG PHARMACEUTICAL CO LTD
10.2.3.1. COMPANY PROFILE
10.2.3.2. PRODUCT LIST
10.2.3.3. STRENGTHS & CHALLENGES
10.2.4. EVOLUS INC
10.2.4.1. COMPANY OVERVIEW
10.2.4.2. PRODUCT LIST
10.2.4.3. STRENGTHS & CHALLENGES
10.2.5. GALDERMA
10.2.5.1. COMPANY OVERVIEW
10.2.5.2. PRODUCT LIST
10.2.5.3. STRENGTHS & CHALLENGES
10.2.6. HUGEL INC
10.2.6.1. COMPANY OVERVIEW
10.2.6.2. PRODUCT LIST
10.2.6.3. STRENGTHS & CHALLENGES
10.2.7. IPSEN
10.2.7.1. COMPANY OVERVIEW
10.2.7.2. PRODUCTS / SERVICES LIST
10.2.7.3. STRENGTHS & CHALLENGES
10.2.8. LANZHOU INSTITUTE OF BIOLOGICAL PRODUCTS CO LTD
10.2.8.1. COMPANY OVERVIEW
10.2.8.2. PRODUCT LIST
10.2.8.3. STRENGTHS & CHALLENGES
10.2.9. MEDYTOX INC
10.2.9.1. COMPANY OVERVIEW
10.2.9.2. PRODUCT LIST
10.2.9.3. STRENGTHS & CHALLENGES
10.2.10. MERZ PHARMA
10.2.10.1. COMPANY OVERVIEW
10.2.10.2. PRODUCT LIST
10.2.10.3. STRENGTHS & CHALLENGES
10.2.11. REVANCE THERAPEUTICS INC
10.2.11.1. COMPANY OVERVIEW
10.2.11.2. PRODUCT LIST
10.2.12. US WORLDMEDS LLC
10.2.12.1. COMPANY OVERVIEW
10.2.12.2. PRODUCT LIST